Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Last updated: December 8, 2023
Sponsor: BioXcel Therapeutics Inc
Overall Status: Terminated

Phase

3

Condition

Dementia

Manic Disorders

Williams Syndrome

Treatment

BXCL501

Matching Placebo

Clinical Study ID

NCT05665088
BXCL501-304
  • Ages > 65
  • All Genders

Study Summary

A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AAcriteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AAdiagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011NIA-AA criteria
  2. Episodes of psychomotor agitation (e.g., kick, bite, flailing)
  3. Subjects exhibit behaviors that are congruent with the International PsychogeriatricAssociation criterion for agitation representing a change from the subject's usualbehavior
  4. A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to fullassistance with activities of daily living
  5. Subjects who read, understand, and provide written informed consent, or who have a LARto provide consent on their behalf
  6. Subjects who are deemed to be medically appropriate for study participation by theprincipal investigator
  7. Participants who agree to use a medically acceptable and effective birth controlmethod

Exclusion

Exclusion Criteria:

  1. Subjects with dementia or other memory impairment not due to probable AD.
  2. Clinical diagnosis of probable AD should not be applied when there is evidence of acerebrovascular incident temporally related to the worsening of cognitive function.
  3. Subjects with agitation caused by acute intoxication.
  4. Subjects with significant risk of suicide or homicide per the investigator'sassessment.
  5. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (>5years) history of stroke may be included, regardless of size/location.
  6. History of clinically significant syncope or syncopal attacks, orthostatic hypotensionwithin the past 2 years, current evidence of hypovolemia, orthostatic hypotension,bradycardia.
  7. Subjects with laboratory or ECG abnormalities.
  8. Subjects who have received an investigational drug within 30 days prior to Screening.
  9. Subjects who are currently suffering from substance abuse.
  10. Subjects with a potential cause for delirium (relatively recent onset agitation anddementia)

Study Design

Total Participants: 13
Treatment Group(s): 2
Primary Treatment: BXCL501
Phase: 3
Study Start date:
December 14, 2022
Estimated Completion Date:
September 11, 2023

Study Description

A randomized, double-blind, placebo-controlled, parallel group, 3-arm study assessing efficacy, safety, and tolerability of two doses of BXCL501 in male and female subjects (65 years and older) with acute psychomotor agitation associated with dementia.

Approximately 150 subjects will participate in this study. Subjects will receive a single film consisting of BXCL501 40 µg dose or BXCL501 60 µg dose or placebo. Subjects must reside in a care facility where all study-related procedures and study drug dosing will be performed.

Connect with a study center

  • BioXcel Clinical Research Site

    Los Alamitos, California 90720
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Daytona Beach, Florida 32117
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Maitland, Florida 32751
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    The Villages, Florida 32162
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Marrero, Louisiana 70072
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Springfield, Massachusetts 01103
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Toms River, New Jersey 08755
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.